Videos

Explore this collection of short videos to learn more about GHD’s work and the issues we focus on.

Non-Communicable Diseases of the “Bottom Billion” – March 2-3, 2011

Gene Bukhman, MD, Partners In Health, discusses the burden of NCDs of the “Bottom Billion,” hopes for the March 2-3 “Long Tail” conference at Harvard and the NCD community on GHDonline.org and a year full of events to build the movement culminating with a UN high-level assembly meeting in September 2011. This interview was done on February 16, 2011 in the offices of Partners In Health, Boston, one of our founding collaborators.

In this section, Gene talks about funding for global health in light of the Obama administration FY2012 Budget and makes the case for addressing endemic NCDs as part of health systems strengthening.

Here, Gene explain what the burden of NCDs is with his perspective as a cardiologist and physician for Partners In Health in Rwanda.Here, Gene explain what the burden of NCDs is with his perspective as a cardiologist and physician for Partners In Health in Rwanda.

Claudine Humure, 18, talks about being diagnosed with cancer in Rwanda, receiving treatment in Boston and now dreaming about becoming a pediatric oncologist to help other children. This interview was done at the  “Long Tail” conference on March 3, 2011.

 

The making of the Global Health Delivery Project at Harvard University

  • Bridging the Delivery Gap to Global Health, Jim Yong Kim at MIT Sloan School of Management – November 19, 2007

  • Global Health Equity, Paul Farmer at MIT School of Humanities, Arts, and Social Sciences – November 15, 2007

  • The Future of Global Health, Jim Yong Kim at Boston University Sargent College of Health and Rehabilitation Sciences – December 4, 2007

Jim Yong Kim discusses the future of global health, highlighting his experiences treating patients in developing nations, in Sargent College’s ninth annual Dudley Allen Sargent Lecture. He discusses his collaboration with the World Health Organization to lower the cost of drugs and the importance of increasing the number of skilled advocates of funding for global health programs.